SEC For	rm 4																			
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB	APPRO		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				TEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											HIP	Estir	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* <u>Murphy Matthew B.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Nautilus Biotechnology, Inc.</u> [ NAUT ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) General Counsel				wner	
	(Last) (First) (Middle) C/O NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVENUE EAST					3. Date of Earliest Transaction (Month/Day/Year) 02/25/2022														
(Street) SEATTLE WA 98102					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)																				
Table I - Non-Deriv   1. Title of Security (Instr. 3)   2. Transa   Date (Month/I)					actio	action 2A. Deemed Execution Date,			3. Transac Code (li 8)	tion	4. Securities Ad Disposed Of (D		cquire	d (A) or	5. Amount of		Form (D) of	vnership 1: Direct r Indirect 1:str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Table II -						uired, Di				Bene		`	iiu 4)		I		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti C	ransad ode (l		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Numl derivati Securiti Benefic Owned Followi Reporte Transac	ive ies ially ng ed	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	t (Instr. 4)	
				c	ode	v	(A)			expiration	Title		Amount or Number of Shares	]	(Instr. 4					

## Explanation of Responses:

\$3.78

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022.

(1)

**Remarks:** 

Stock Option

(Right to Buy)

## /s/ Matthew B. Murphy

Common

Stock

02/25/2032

140,000

\*\* Signature of Reporting Person Date

\$<mark>0</mark>

140,000

02/25/2022

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/25/2022

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

140,000